22/01/2024

eHealth Ventures Invests in Wizermed, Revolutionizing...

eHealth Ventures Invests in Wizermed, Revolutionizing Migraine Management with AI Innovation

We are proud to announce our most recent investment in Wizermed, a pioneering AI-based company dedicated to migraine management and prediction. 

 

Migraines impose a significant burden on the lives of those affected by them. The unpredictability of these attacks exacerbates the challenge, significantly affecting patients’ quality of life. Over 1 billion people, around 15% of the global population, suffer from migraines and the debilitation they cause.  In the United States, migraines afflict more than 40 million individuals. The economic costs are staggering, with an estimated annual cost of $78 billion in direct and indirect expenses in the United States alone.  

 

In order to combat chronic migraines, Wizermed is developing “Migraine Predict”—a novel AI-based mobile app designed to predict and manage migraine attacks effectively. This innovative solution forecasts migraine episodes with remarkable accuracy, providing patients with real-time alerts 24 hours prior to the onset of an attack.  

 

“Migraine Predict” offers early forecasts of migraine episodes and personalized recommendations to users, empowering them to gain control over their migraine episodes. The app features tailored recommendations for short-term behavioral changes while alerting patients of the optimal time they can take their medications based on their physician’s input before the onset of an attack. The early behavioral and pharmaceutical interventions substantially reduce the duration and severity of a migraine attack.  

 

Wizermed’s innovative product is rooted in cutting edge research, utilizing data gathered via a continuous monitoring of smartwatch sensors from hundreds of participants in clinical trials. Leveraging advanced ML and AI algorithms, the extensive dataset has been harnessed to develop migraine prediction models. Long-term and consistent use of “Migraine Predict” is expected to reduce the intensity, duration, and frequency of migraine attacks. 

 

Migraine Predict is a promising and innovative solution for individuals plagued by migraines.  

 

CEO Guy Attar comments: “This investment marks a significant milestone for our company and sets the stage for an exciting journey ahead. At Wizermed, we are dedicated to providing effective remedy for migraine relief.  With the support of eHealth Ventures, we are now poised to take our vision to the next level, fueling innovation and growth in digital health solutions. We’re incredibly grateful for the confidence and trust that eHealth Ventures has placed in us, and we’re committed to delivering outstanding results as we embark on this journey together.” 

 

eHealth Ventures is optimistic at the prospect of the new investment. Ophir Shahaf, VP of BD comments: “Wizermed presents a highly innovative solution to one of the most prevalent and debilitating medical issues – Migraines. By utilizing advanced data science and personalization, their prediction will reduce dependence on medication and provide true benefits to many patients. The team is highly experienced and brings a wealth of scientific, clinical and commercial experience – so we look forward to their value building and success within eHealth Ventures.”  

About eHealth Ventures

The eHealth Ventures partnership is a leading investor in early-stage digital health companies.
It includes 2 VC funds and a technological incubator with an exclusive focus on digital health and significant government non-dilutive funding. Partners include Maccabi (a leading Israeli HMO), Amgen (global biotech giant), the Mayo Clinic, Medison Ventures, Arad Investments, and the Hadar Group. The team has reviewed over 1,650 companies to date and invested in a portfolio of 24 highly innovative companies (digital diagnostics, therapeutics, home care and Bioconvergence).

Get in Touch